RXO INC (RXO) Fundamental Analysis & Valuation

NYSE:RXO • US74982T1034

Current stock price

16.01 USD
-0.25 (-1.54%)
At close:
16.01 USD
0 (0%)
After Hours:

This RXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RXO Profitability Analysis

1.1 Basic Checks

  • In the past year RXO has reported negative net income.
  • In the past year RXO had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: RXO reported negative net income in multiple years.
  • RXO had a positive operating cash flow in 4 of the past 5 years.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • RXO's Return On Assets of -3.05% is on the low side compared to the rest of the industry. RXO is outperformed by 66.67% of its industry peers.
  • RXO has a worse Return On Equity (-6.49%) than 66.67% of its industry peers.
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROIC N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • Looking at the Gross Margin, with a value of 16.39%, RXO is doing worse than 71.43% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RXO has declined.
  • The Profit Margin and Operating Margin are not available for RXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RXO Health Analysis

2.1 Basic Checks

  • RXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RXO has more shares outstanding
  • Compared to 5 years ago, RXO has more shares outstanding
  • RXO has a worse debt/assets ratio than last year.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • RXO has an Altman-Z score of 2.59. This is not the best score and indicates that RXO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of RXO (2.59) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.25 indicates that RXO is not too dependend on debt financing.
  • RXO has a Debt to Equity ratio of 0.25. This is comparable to the rest of the industry: RXO outperforms 57.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 2.59
ROIC/WACCN/A
WACC10.45%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • RXO has a Current Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of RXO (1.27) is comparable to the rest of the industry.
  • RXO has a Quick Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.27, RXO is in line with its industry, outperforming 59.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RXO Growth Analysis

3.1 Past

  • RXO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -145.45%.
  • Looking at the last year, RXO shows a very strong growth in Revenue. The Revenue has grown by 26.20%.
  • RXO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.33% yearly.
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%

3.2 Future

  • RXO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 155.84% yearly.
  • The Revenue is expected to grow by 9.55% on average over the next years. This is quite good.
EPS Next Y127.09%
EPS Next 2Y215.99%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. RXO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXO. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 1182.06, which means the current valuation is very expensive for RXO.
  • Based on the Price/Forward Earnings ratio, RXO is valued a bit more expensive than the industry average as 64.29% of the companies are valued more cheaply.
  • RXO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.68.
Industry RankSector Rank
PE N/A
Fwd PE 1182.06
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 500 1K

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RXO is valued a bit more expensive than 71.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.67
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • RXO's earnings are expected to grow with 155.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y215.99%
EPS Next 3Y155.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXO Dividend Analysis

5.1 Amount

  • No dividends for RXO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXO Fundamentals: All Metrics, Ratios and Statistics

RXO INC

NYSE:RXO (4/9/2026, 8:04:00 PM)

After market: 16.01 0 (0%)

16.01

-0.25 (-1.54%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)02-06
Earnings (Next)04-30
Inst Owners108.81%
Inst Owner Change0%
Ins Owners0.71%
Ins Owner Change2.22%
Market Cap2.63B
Revenue(TTM)5.74B
Net Income(TTM)-100.00M
Analysts66.92
Price Target16.52 (3.19%)
Short Float %9.37%
Short Ratio6.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.97%
Min EPS beat(2)-79.64%
Max EPS beat(2)-72.3%
EPS beat(4)1
Avg EPS beat(4)-27.69%
Min EPS beat(4)-79.64%
Max EPS beat(4)101.04%
EPS beat(8)5
Avg EPS beat(8)-6.09%
EPS beat(12)8
Avg EPS beat(12)38.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)-1.8%
Revenue beat(8)1
Avg Revenue beat(8)-1.36%
Revenue beat(12)2
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.73%
PT rev (3m)4.37%
EPS NQ rev (1m)-8.82%
EPS NQ rev (3m)-105.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-92.09%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1182.06
P/S 0.46
P/FCF N/A
P/OCF 51.54
P/B 1.71
P/tB N/A
EV/EBITDA 27.67
EPS(TTM)-0.05
EYN/A
EPS(NY)0.01
Fwd EY0.08%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.31
OCFY1.94%
SpS34.97
BVpS9.39
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
F-Score5
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 3.55
Cap/Depr 50.86%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion 46.79%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.59
F-Score5
WACC10.45%
ROIC/WACCN/A
Cap/Depr(3y)66.04%
Cap/Depr(5y)62.51%
Cap/Sales(3y)1.22%
Cap/Sales(5y)1.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y127.09%
EPS Next 2Y215.99%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%
EBIT growth 1Y-123.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year139.58%
EBIT Next 3Y84.98%
EBIT Next 5Y60.59%
FCF growth 1Y85.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y525%
OCF growth 3Y-45.21%
OCF growth 5Y15.33%

RXO INC / RXO Fundamental Analysis FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXO.


What is the valuation status for RXO stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


How profitable is RXO INC (RXO) stock?

RXO INC (RXO) has a profitability rating of 1 / 10.


Can you provide the financial health for RXO stock?

The financial health rating of RXO INC (RXO) is 3 / 10.